奥沙利铂(Oxaliplatin) - 药物靶点：DNA_在研适应症：小肠癌，胃癌，胰腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Diaminocyclohexane Oxalatoplatinum、GSOX、L-OHP

+ [36]

靶点

DNA

作用机制

DNA抑制剂(DNA抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [5]

在研适应症

小肠癌胃癌胰腺癌+ [17]

非在研适应症

急性髓性白血病晚期胆管癌晚期癌症+ [90]

原研机构

Sanofi

在研机构

Merck Sharp & Dohme Corp.Hoffmann-La Roche, Inc.

Seagen Inc.

+ [4]

非在研机构

Eli Lilly & Co.Roche Pharma AG

Sanofi

+ [16]

最高研发阶段批准上市

首次获批日期

中国 (2000-01-01),

肿瘤

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C8H14N2O4Pt

InChIKeyZROHGHOFXNOHSO-BNTLRKBRSA-L

CAS号61825-94-3

关联

2,389

项与奥沙利铂相关的临床试验

NCT06719362 / Not yet recruiting临床1期IIT

A First-in-human, Open-label, Dose Escalation, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies in Patients With Advanced Solid Tumors

Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoclonal antibody targeting FasL) in subjects with metastatic or unresectable solid tumors.

开始日期2025-02-01

申办/合作机构

Providence Health & Services

NCT06245356 / Not yet recruiting临床2期IIT

TRIFLUOX-DP: Safety of Trifluridine/Tipiracil as Replacement of Fluoropyrimidines (5-fluorouracil and Capecitabine) Based Chemotherapy as First Line Metastatic Colorectal or Gastroesophageal Cancer Regimens in Patients With Dihydropyrimidine Dehydrogenase Deficiency: a Phase II Trial

The goal of this clinical trial is to test the safety of the trifluridine/tipiracil as replacement of fluoropyrimidines based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.
The main questions it aims to answer are:
* Is this alternative chemotherapy option a better option in term of safety for this type of patients?
* Does the combination of treatments improves the overall safety?
* Does the combination of treatments improves the progression-free survival, overall survival, objective response rate and disease control rate?
* Does the combination of treatment have an effect on quality of life?
Participants will:
* Receive the trifluridine/tipiracil with oxaliplatin every 14 days, associated with:
* Panitumumab or bevacizumab for colorectal adenocarcinomas
* Nivolumab or trastuzumab for gastroesophageal adenocarcinomas.
* Have a CT-Scan every 2 months until disease progression
* Complete Health-related quality of life questionnaire every 2 months for a maximum of 6 months
* Participate to the optional translational research: Blood samples fo DPYD genotyping and pharmacokinetic analysis

开始日期2025-01-31

申办/合作机构

UNICANCER

[+1]

NCT05314998 / Not yet recruiting临床3期IIT

An Open Labelled Phase III Adjuvant Trial of Disease-free Survival in Patients With Resected Pancreatic Ductal Adenocarcinoma Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

This is a multicentre open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria (control arm) or by a transcriptomic treatment specific stratification signature or TSS (test arm).

开始日期2025-01-15

申办/合作机构

Heidelberg University, U.S.

[+3]

100 项与奥沙利铂相关的临床结果

登录后查看更多信息

100 项与奥沙利铂相关的转化医学

登录后查看更多信息

100 项与奥沙利铂相关的专利（医药）

登录后查看更多信息

14,177

项与奥沙利铂相关的文献（医药）

2025-12-01·Journal of Gastrointestinal Cancer

Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer

Article

作者: Gou, Miaomiao ; Qian, Niansong ; Dai, Guanghai ; Zhang, Yong ; Wang, Zhikuan

BACKGROUND:

The survival benefit from later-line treatment for patients with metastatic colorectal cancer (mCRC) remains disappointing. Here, in a real-world study, we were aimed to evaluate which choice will affect the survival of mCRC patients after standard treatment in Chinese patients.

METHODS:

A total of 129 patients with refractory mCRC were involved in the study. They received targeted monotherapy or combined with chemo-agents or PD-1 inhibitor before death. Overall survival (OS) and progression-free survival (PFS) were reviewed and evaluated from clinical features and treatment options.

RESULTS:

Among the 129 patients, the median age was 56 years (25-81). The mOS from third-line was 12.5 months. OS of patients who treated with chemo plus targeted therapy group in third-line was shown to be superior to pd-1 inhibitor in combination with antiangiogenic agents or antiangiogenic monotherapy group (15.6 m vs. 10.5 m vs. 8.4 m, p < 0.05). Patients had received triplet-drugs (bevacizumab plus low-dose irinotecan and oxaliplatin) and had prolonged survival compared to those had not (21.3 m vs 10.3 m, p = 0.004). OS between patients who had immunotherapy history or not was not significantly different (p > 0.05). The mPFS was 3.5 months in patients who had administered with antiangiogenic targeted agents plus anti-pd-1 and 4.7 months in chemo plus targeted therapy group and 2.2 months in the other group. In the triplet drugs group, preliminary results showed that ORR was 13.3% and DCR was 80%. The median PFS was 5.1 m, and the median OS was 10.6 m.

CONCLUSIONS:

Triplet drugs resulted in significantly longer overall survival, and immunotherapy may have limited benefit in MSS type CRC patients.

2025-02-01·NEUROPHARMACOLOGY

Humanin attenuates metabolic, toxic, and traumatic neuropathic pain in mice by protecting against oxidative stress and increasing inflammatory cytokine

Article

作者: Hekim, Munevver Gizem ; Ayar, Ahmet ; Kelestemur, Muhammed Mirac ; Canpolat, Sinan ; Ozcan, Mete ; Bilgin, Batuhan ; Ozcan, Sibel ; Bulut, Ferah ; Adam, Muhammed

Neuropathic pain is associated with diverse etiologies, including sciatica, diabetes, and the use of chemotherapeutic agents. Despite the varied origins, mitochondrial dysfunction, oxidative stress, and inflammatory cytokines are recognized as key contributing factors in both the initiation and maintenance of neuropathic pain. The effects of the mitochondrial-derived peptide humanin on neuropathic pain, however, remain unclear, despite its demonstrated influence on these mechanisms in numerous disease models. This study aimed to evaluate the effects of humanin on pain behavior in murine models of metabolic (streptozotocin/STZ), toxic (oxaliplatin/OXA), traumatic (sciatic nerve cuffing/cuff), and neuropathic pain. A secondary objective was to assess whether humanin modulates oxidative damage and inflammatory cytokine levels in these neuropathic pain models. Humanin (4 mg/kg) was administered intraperitoneally (i.p.) to BALB/c male mice with induced neuropathic pain over a period of 15 days, with pain thresholds assessed using hot plate, cold plate, and Von Frey tests. Serum levels of antioxidant enzymes, oxidative stress markers, and inflammatory/anti-inflammatory cytokines were measured via enzyme-linked immunosorbent assay (ELISA). In neuropathic pain-induced mice, humanin administration resulted in a statistically significant increase in pain threshold values in the STZ + Humanin, OXA + Humanin, and cuff + Humanin groups compared to their respective control groups (P < 0.05) over 15 days. Furthermore, humanin treatment significantly elevated antioxidant enzyme levels and anti-inflammatory cytokine concentrations, while reducing oxidative stress markers and pro-inflammatory cytokine levels compared to control groups (P < 0.01). These findings suggest that humanin exhibits therapeutic potential in the treatment of neuropathic pain induced by STZ, OXA, and cuff models. The ability of humanin to mitigate neuropathic pain through the suppression of oxidative stress and inflammatory cytokines indicates its promise as a novel therapeutic strategy.

2025-02-01·Clinical Nutrition ESPEN

Skeletal muscle is independently associated with grade 3–4 toxicity in advanced stage pancreatic ductal adenocarcinoma patients receiving chemotherapy

Article

作者: Coolsen, Mariëlle M.E. ; Damink, Steven W.M. Olde ; Van Dam, Ronald M. ; Volmer, Leroy ; Brecheisen, Ralph ; Aberle, Merel R ; Aberle, Merel R. ; Rensen, Sander S. ; Wenmaekers, Gilles ; Van Dam, Ronald M ; de Vos-Geelen, Judith ; van Dijk, David ; Damink, Steven W M Olde ; Wee, Leonard ; Coolsen, Mariëlle M E ; Rensen, Sander S

BACKGROUND:

Patients with advanced-stage pancreatic ductal adenocarcinoma (PDAC) are regularly treated with FOLFIRINOX, a chemotherapy regimen based on 5-fluorouracil, irinotecan and oxaliplatin, which is associated with high toxicity. Dosing of FOLFIRINOX is based on body surface area, risking under- or overdosing caused by altered pharmacokinetics due to interindividual differences in body composition. This study aimed to investigate the relationship between body composition and treatment toxicity in advanced stage PDAC patients treated with FOLFIRINOX.

METHODS:

Data from patients treated at the Maastricht University Medical Centre + between 2012 and 2020 were collected retrospectively (n = 65). Skeletal muscle-, visceral adipose tissue, subcutaneous adipose tissue-, (SM-Index, VAT-Index, SAT-Index resp.) and Skeletal Muscle Radiation Attenuation (SM-RA) were calculated after segmentation of computed tomography (CT) images at the third lumbar level using a validated deep learning method. Lean body mass (LBM) was estimated using SM-Index. Toxicities were scored and grade 3-4 adverse events were considered dose-limiting toxicities (DLTs).

RESULTS:

Sixty-seven DLTs were reported during the median follow-up of 51.4 (95%CI 39.2-63.7) weeks. Patients who experienced at least one DLT had significantly higher dose intensity per LBM for all separate cytotoxics of FOLFIRINOX. Independent prognostic factors for the number of DLTs per cycle were: sarcopenia (β = 0.292; 95%CI 0.013 to 0.065; p = 0.013), SM-Index change (% per 30 days, β = -0.045; 95%CI -0.079 to -0.011; p = 0.011), VAT-Index change (% per 30 days, β = -0.006; 95%CI -0.012 to 0.000; p = 0.040) between diagnosis and the first follow-up CT scan, and cumulative relative dose intensity >80 % (β = -0.315; 95 % CI -0.543 to -0.087; p = 0.008).

CONCLUSION:

Sarcopenia and early muscle and fat wasting during FOLFIRINOX treatment were associated with treatment-related toxicity, warranting exploration of body composition guided personalized dosing of chemotherapeutics to limit DLTs.

1,176

项与奥沙利铂相关的新闻（医药）

2024-12-13

·医药笔记

恒瑞医药：SHR-A1811卵巢癌拟纳入突破性治疗

▎Armstrong 2024年12月20日，恒瑞医药HER2 ADC新药SHR-A1811治疗HER2表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌拟纳入突破性治疗药物程序。此前，SHR-A1811已有6项适应症纳入突破性治疗药物，包括HER2阳性的复发或转移性乳腺癌，HER2低表达的复发或转移性乳腺癌，既往含铂化疗失败的HER2突变的晚期非小细胞肺癌，既往经奥沙利铂、氟尿嘧啶和伊立替康治疗失败、HER2阳性结直肠癌，HER2阳性晚期胃癌或胃食管结合部腺癌，既往接受过一种或一种以上治疗方案的HER2阳性不可切除或转移性胆道癌。 SHR-A1811为第三代HER2 ADC，抗体采用曲妥珠单抗，payload为自主研发的SHR169265，DAR值为6。 SHR169265的活性比DXd类似物SHR167971强3倍左右。总结 SHR-A1811于今年9月递交上市申请，用于治疗既往接受过至少一种系统治疗的局部晚期或转移性HER2突变成人非小细胞肺癌。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

抗体药物偶联物突破性疗法申请上市

2024-12-13

·Insight数据库

第 7 次！恒瑞 HER2 ADC 新适应症拟纳入突破性治疗

12 月 13 日，CDE 官网显示，恒瑞注射用 SHR-A1811（瑞康曲妥珠单抗）拟被纳入突破性疗法，用于治疗 HER2 表达的铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌。此前瑞康曲妥珠单抗已经有 6 次纳入突破性治疗，若是此次通过公示，将成为该药物的第 7 次突破性疗法认定。截图来源：CDE 官网瑞康曲妥珠单抗是恒瑞医药自主研发的 HER2 ADC，由曲妥珠单抗、可裂解连接子及拓扑异构酶 I 抑制剂有效载荷 SHR169265 组合而成，其有效载荷 SHR169265 不仅具有更高的膜穿透能力，还显著增强了细胞杀伤效果。更关键的是，该药物在连接子与毒素之间创新性地引入了手性环丙基设计，极大地提升了药物化学稳定性，有效控制了毒素的精准释放，并显著降低了早期释放可能引发的副作用。值得一提的是，此前瑞康曲妥珠单抗已经有 6 个适应症获得突破性疗法认定：用于 HER2 阳性的复发或转移性乳腺癌患者；用于 HER2 低表达的复发或转移性乳腺癌；单药治疗既往含铂化疗失败的 HER2 突变的晚期非小细胞肺癌（NSCLC）患者；单药治疗既往经奥沙利铂、氟尿嘧啶和伊立替康治疗失败、HER2 阳性结直肠癌；既往至少一线抗 HER2 治疗失败的 HER2 阳性晚期胃癌或胃食管结合部腺癌患者；用于既往接受过一种或一种以上治疗方案的 HER2 阳性不可切除或转移性胆道癌患者。截图来源：CDE 官网纵观全球研究情况来看，目前有 3 款 HER2 ADC 新药已获批上市，分别是荣昌生物的维迪西妥单抗、第一三共的德曲妥珠单抗和 ImmunoGen 的恩美曲妥珠单抗。仅荣昌生物一款是国产。截图来源：Insight 数据库其他国产 HER2 ADC 新药处于上市申请阶段的有 2 款，分别来自恒瑞的瑞康曲妥珠单抗和科伦药业的博度曲妥珠单抗。截图来源：Insight 数据库除此以外，进入临床 III 期阶段的有 6 款，分别来自百利天恒、正大天晴、石药集团、康宁杰瑞、映恩生物和乐普生物。截图来源：Insight 数据库由此可见，恒瑞在国产 HER2 ADC 领域处于第一梯队。并且瑞康曲妥珠单抗在国产同类药物中获得的突破性疗法认定最多的，其中多个在研适应症大都是进度相对靠前，例如：在 HER2 阳性结直肠癌领域，全球尚无 HER2 ADC 获批，恒瑞在同类产品中的进度第一，正在国内开展 Ⅲ 期临床。在 HER2 阳性晚期胃癌或胃食管结合部腺癌领域，目前有两款产品获批（德曲妥珠单抗、维迪西妥单抗），恒瑞进度第三，正在开展 Ⅲ 期临床。在 HER2 低表达复发或转移性乳腺癌领域，国内目前仅有德曲妥珠单抗获批，恒瑞正在开展 Ⅲ 期临床；在 HER2 阳性不可切除或转移性胆道癌领域，全球尚无 HER2 ADC 获批。同类产品中，德曲妥珠单抗进度最快，正在开展 Ⅲ 期临床，恒瑞正在国内开展 Ⅱ 期临床。封面来源：企业 Logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：ccai PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验点击阅读原文，立刻解锁！

突破性疗法临床3期抗体药物偶联物

2024-12-13

·UmabsDB

一线胃癌头对头：第一三共启动HER2 ADC+PD-1三期临床

Umabs DB作为目前全球最全面的抗体药物专业数据库，收录全球近10000个从临床前到商业化阶段抗体药物，涉及靶点1600+，涉及疾病种类2400+，研发机构2900+，覆盖药物蛋白序列、专利和临床等多种专业信息。Umabs DB药物数据库已正式开放上线，可访问www.umabs.com注册享受7天免费试用。近期，根据UmabsDB数据库的记录，第三一共在clinical trials网站上，登记了一项HER2 ADC药物trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) ，联合PD-1抗体pembrolizumab和fluoropyrimidine，在HER2阳性PD-L1 CPS ≥1一线胃癌患者中启动一项3期头对头临床试验NCT06731478，该临床将于2025年3月启动，计划入组人数为726例。该临床分为两个队列的头对头临床试验，队列一：T-DXd+fluoropyrimidine (5-FU or capecitabine)+pembrolizumab，对照组为Trastuzumab+platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine) +pembrolizumab，队列二：T-DXd+fluoropyrimidine (5-FU or capecitabine)，对照组为Trastuzumab+platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine)，PFS作为主要临床重点，OS作为次要临床终点。此前T-DXd已经获批用于二线HER2阳性的胃癌患者治疗，日本和韩国患者参与的 DESTINY-Gastric01 II期临床研究显示，接受T-DXd治疗的HER2阳性转移性胃癌患者的确认的客观缓解率（ORR）（T-DXd组为40.5%，化疗组为11.3%；p<0.0001）和中位总生存期（OS）（T-DXd组为12.5个月，化疗组为8.4个月；风险比[HR]0.59）显示出统计学的显著改善。此前，基于DESTINY-Gastric01/02研究结果，T-DXd单抗已在美国、日本、欧盟和中国等超过45个国家和地区获批。 HER2阳性的一线胃癌治疗方面，曲妥珠单抗联合PD-1抗体pembrolizumab目前是唯一获批的方案。该三期临床KEYNOTE-811，698例接受随机分配的患者中，594例（85%）为肿瘤表达PD-L1且CPS≥1。 KEYNOTE-811 研究（IA3） PD-L1 CPS≥1 人群 PFS 结果 2023年欧洲肿瘤内科学会（ESMO）年会上，KEYNOTE-811研究公布的数据显示，与曲妥珠单抗+化疗相比，帕博利珠单抗+曲妥珠单抗+化疗一线治疗在PD-L1 CPS≥1人群（mPFS 10.9 vs 7.3个月，HR=0.71）中具有更佳的无进展生存期（PFS）；帕博利珠单抗组客观缓解率（ORR）改善（72.6% vs 59.8%）且反应持续（mDoR 11.2 vs 9.0个月）。 KEYNOTE-811 研究（IA3） PD-L1 CPS≥1 人群 OS 结果 2024年5月，默沙东宣布KEYNOTE-811研究已达到除了PFS之外的第二个主要终点，即总生存期（OS）。并且，目前得出的OS获益情况也与PFS的获益情况一致，即PD-L1阳性（CPS≥1）胃癌/胃食管交界处腺癌患者获益最为明显。OS阳性结果的出炉，进一步验证了帕博利珠单抗+曲妥珠单抗+化疗方案作为HER2阳性晚期胃癌患者的一线治疗的疗效，期待第一三共的ADC三联治疗方案能够取得新的突破。 ENHERTU虽然目前获批五个适应症，但从细分区域来看，全球呈现怠涨状态。美国占据了全球一半以上的销售额，4月份随着泛癌种的适应症批准，销售额稍有抬头，但仍然不够显著。 2024Q3欧洲仍然处于平台阶段，单季度为1.3亿美元左右，同时发展中国家增速也有所降低，特别是随着中国区域陷入骗保和走私泥潭，这一区域的销售情况将显著受到负影响。根据目前的销售情况，Enhertu在2024年全球销售预计将超过36亿美金，希望屡创临床奇迹的Enhertu在销售额上同样获得成功，以激励更多创新药物进行研发。期待该临床早日传来临床捷报，更多有关抗体的研发格局、具体信息、专利及临床等动态进展，敬请访问Umabs DB全球数据库（www.umabs.com）查阅。拓展阅读： PD-1+TIGIT：吉利德启动一线头颈鳞癌联合疗法临床 Celldex启动KIT抗体特应性皮炎2期临床中位OS提高10.9个月：Immutep启动LAG-3+PD-1一线非小细胞肺癌头对头三期临床试验 Macrogenics启动下一代ADAM9 ADC临床 100% CR：默沙东更新ROR1 ADC二期淋巴瘤临床数据，即将启动三期临床 MSD：收购PD-1/VEGF双抗后的回应 HIV：中裕新药将ADC拓展至抗病毒领域全球首个：默沙东ROR1 ADC启动三期临床试验 HER3终成药：HER2/HER3双抗Zenocutuzumab获FDA批准上市百利天恒两款ADC在美启动临床 3000万美元首付：GSK引进映恩一款临床前ADC药物 “四字编码”时代下的信达全梳理 BioNtech启动PD-L1/VEGF双抗肺癌两项头对头三期临床大涨68%：Janux的PSMA/CD3双抗再次取得突破疗效 316例：诺华启动BAFF-R抗体在狼疮性肾炎的三期临床 250例：默克CEACAM5 ADC开展泛癌种临床试验 AK112 vs PM8002：PD-1/VEGF第三次交锋康方生物两款PD-1双抗均进入2024年医保目录 234例：安领科启动EGFR/c-Met双抗ADC临床科伦博泰：本土首款Trop2 ADC获批上市罗氏TIGIT抗体一线肺癌再次失败 876例：恒瑞启动c-met ADC单药及多种药物联用临床科伦博泰首个双抗ADC启动临床阿斯利康：ADC药物的临床剂量转化策略最惨18A：北海康成市值仅为7520万港元，累计跌幅达到98.55% 2~3分钟完成给药：K药皮下制剂三期临床取得成功 ORR仅为5%：Immatics公布PRAME/CD3 TCR双抗临床数据石药启动EGFR ADC+ATM抑制剂联合治疗临床康方启动CD73/LAG3双抗临床试验宫颈癌：迈威Nectin-4 ADC启动第3项三期临床大涨53%：中国资产再次拯救美股biotech 翰森HS-20124为ROR-1 ADC药物？翰森公开SEZ6 ADC专利翰森公开CDH17 ADC专利复宏汉霖公布两款ADC药物专利 BioNtech: 2024研发日默沙东终于信了：5.88亿美元首付款引进礼新PD-1/VEGF双抗映恩公开PD-L1/B7H3双抗ADC临床前数据 Hexagon：新型ADC毒素提高渗透性：antikor开发高DAR值片段抗体ADC Genmab终止两款CD3双抗开发，重聚焦后期管线第一三共开发皮下HER2 ADC 三抗来袭：Aditum Bio以3500万美元首付款引进维立志博CD3/CD19/BCMA 强生公布膜依赖性MSLN/CD3双抗金赛公开自主开发TOPOi ADC平台礼来公布PTK7 ADC药物临床前数据双payload ADC逐步工业化，多款药物即将进入临床恒瑞SHR-A2009：国内首个HER3 ADC进入三期 ADC：抗原高表达的必要性？关于Umabs DB Umabs DB是目前全球最全面的抗体药物专业数据库，收录全球近10000个从临床前到商业化阶段抗体药物，涉及靶点1600+，涉及疾病种类2400+，研发机构2900+，覆盖药物蛋白序列、专利和临床等多种专业信息。Umabs DB药物数据库已正式开放上线，可访问www.umabs.com注册享受7天免费试用，更多信息可联系info@umabs.com

临床3期抗体药物偶联物临床结果临床2期临床失败

100 项与奥沙利铂相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01790	奥沙利铂	L01XA03	DB00526

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
小肠癌	日本	Yakult Honsha Co., Ltd.	2018-09-21
胃癌	日本	Yakult Honsha Co., Ltd.	2015-03-20
胰腺癌	日本	Yakult Honsha Co., Ltd.	2013-12-20
结直肠癌	美国	Sanofi-Aventis U.S. LLC	2007-01-10
晚期结直肠腺癌	澳大利亚	Medis Pharma Pty Ltd.	2006-11-28
结肠癌	美国	Sanofi-Aventis U.S. LLC	2002-08-09
直肠癌	美国	Sanofi-Aventis U.S. LLC	2002-08-09
肿瘤	中国	南京制药厂有限公司	2000-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	临床3期	美国	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	中国	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	澳大利亚	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	比利时	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	丹麦	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	法国	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	德国	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	波兰	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	波多黎各	Hoffmann-La Roche, Inc.	2021-02-23
弥漫性大B细胞淋巴瘤	临床3期	韩国	Hoffmann-La Roche, Inc.	2021-02-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03217097 (MGMT-NET, Pubmed \| J Clin Oncol)	临床2期	神经内分泌肿瘤	105	Alkylating agents	憲淵遞醖艱獵獵鬱繭鑰(廠觸網夢簾齋糧願鹽鹹) = 糧選範構憲憲顧淵醖鏇獵糧艱夢遞願鏇遞網顧 (蓋襯鏇衊願襯積範觸選 ) 更多	积极	2024-11-25
NCT03217097 (MGMT-NET, Pubmed \| J Clin Oncol)	临床2期	神经内分泌肿瘤	105	Oxaliplatin	憲淵遞醖艱獵獵鬱繭鑰(廠觸網夢簾齋糧願鹽鹹) = 醖獵鏇網衊壓齋遞鑰壓獵糧艱夢遞願鏇遞網顧 (蓋襯鏇衊願襯積範觸選 ) 更多	积极	2024-11-25
NCT03259035 (CCTG CO.28 \| NEO \| CO.28, CTgov)	临床2期	直肠癌	58	folinic acid+oxaliplatin+capecitabine+fluorouracil	顧餘鹹網網醖齋積艱製(夢鏇膚繭鏇廠壓窪鹹夢) = 淵憲糧獵襯遞範築鑰鑰遞鹽築範糧觸餘醖廠觸 (繭顧衊鏇齋獵製餘觸廠, 遞醖觸衊鹹廠願鑰夢製 ~ 遞窪鹹構淵獵鏇窪齋衊) 更多	-	2024-10-10
NCT03483038 (NEO-Nal-IRI, CTgov)	临床2期	胰腺腺癌	45	LEUCOVORIN CALCIUM+Liposomal Irinotecan+Oxaliplatin+Fluorouracil	醖製構鬱壓製鹽餘製觸(膚網築築糧襯廠淵襯鹹) = 遞築構鏇鑰憲淵獵糧觸鏇襯憲獵遞鏇醖齋鬱鑰 (顧醖選鹹醖鑰糧觸遞簾, 鹹鏇鹽選簾獵鹹淵襯蓋 ~ 醖餘衊齋鬱窪廠襯襯遞) 更多	-	2024-09-23
NCT03388190 (METIMMOX, ESMO2024)	临床2期	转移性微卫星稳定结直肠癌一线 TMB \| BRAF-V600E \| CRP	34	FLOX (oxaliplatin, 5-fluorouracil, folinic acid) Q2W	糧範願餘鬱糧艱憲鏇糧(積選鹹積構簾醖築憲遞) = 憲鏇鬱築蓋獵夢夢簾餘獵襯醖顧積鑰窪糧蓋艱 (網製餘積鹽構鏇積製壓 ) 更多	积极	2024-09-16
SOHO2024	N/A	弥漫性大B细胞淋巴瘤	-	AZA+ R-GemOx	鬱構襯窪壓鏇繭夢製蓋(艱窪廠獵餘顧獵選繭衊) = Grades 3–4 adverse events were mainly hematological, and all toxicities were transient and reversible 鏇繭鏇網艱膚膚繭獵觸 (廠憲衊鏇齋築選繭夢獵 )	-	2024-09-04
NCT01595321 (CTgov)	临床2期	胰腺腺癌	19	Stereotactic Body Radiation+Leucovorin Calcium+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (Cohort 1: SBRT and FOLFIRINOX)	壓積膚壓醖範糧願憲夢(醖鏇襯淵觸膚襯製願襯) = 顧膚網鏇艱鑰積願鏇餘製襯壓餘觸蓋齋夢淵襯 (網積構簾觸願鏇鑰鏇築, 網廠窪糧網鹽壓鑰積醖 ~ 餘衊鏇廠鏇糧願製鹽窪) 更多	-	2024-08-14
NCT01595321 (CTgov)	临床2期	胰腺腺癌	19	Stereotactic Body Radiation (Cohort 2: SBRT and Modified FOLFIRINOX)	壓積膚壓醖範糧願憲夢(醖鏇襯淵觸膚襯製願襯) = 選壓蓋顧蓋窪積壓餘繭製襯壓餘觸蓋齋夢淵襯 (網積構簾觸願鏇鑰鏇築, 膚鏇憲窪餘膚鹹膚餘獵 ~ 膚衊廠淵艱選範簾鬱觸) 更多	-	2024-08-14
NCT01515748 (PRODIGY, Pubmed)	临床3期	晚期胃癌新辅助 \| 辅助	-	Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1	憲蓋鏇築窪願範糧鑰鹽(觸範網鏇願壓壓艱積顧) = 簾窪鹽範願醖艱繭糧網鏇繭醖獵齋鏇築獵壓艱 (繭鏇獵觸醖獵艱醖繭壓 )	积极	2024-07-12
NCT02352337 (PRODIGE 35-PANOPTIMOX \| PANOPTIMOX, CTgov)	临床2期	胰腺继发性恶性肿瘤	276	Leucovorin Calcium+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (FOLFIRINOX)	窪鏇餘鹹簾鬱衊願獵壓(獵顧鹹壓鬱積積襯餘築) = 構憲衊膚鏇遞鏇襯壓構糧蓋糧衊鬱淵構艱範遞 (窪鬱簾範夢獵鏇觸餘鹽, 鏇淵顧廠艱鏇淵醖餘齋 ~ 齋繭獵夢醖構鑰醖觸餘) 更多	-	2024-07-10
NCT02352337 (PRODIGE 35-PANOPTIMOX \| PANOPTIMOX, CTgov)	临床2期	胰腺继发性恶性肿瘤	276	LV+irinotecan+oxaliplatin+Irinotecan hydrochloride+FLUOROURACIL (FOLFIRINOX + LV5FU2 in Maintenance)	窪鏇餘鹹簾鬱衊願獵壓(獵顧鹹壓鬱積積襯餘築) = 膚積鏇範鬱壓築鑰鏇繭糧蓋糧衊鬱淵構艱範遞 (窪鬱簾範夢獵鏇觸餘鹽, 製積鑰淵範積觸膚鹹糧 ~ 艱顧網製窪膚襯觸鑰衊) 更多	-	2024-07-10
IRCT20140903019036N3 (ESMO_GI2024) 人工标引	临床2期	食管癌新辅助	59	Carboplatin/Paclitaxel (CP) regimen	襯願糧壓糧網繭淵遞鹹(餘鬱淵糧淵廠艱願窪餘) = 餘觸夢顧鹹製憲壓願襯鏇顧餘糧窪膚鏇鬱鹹醖 (遞鑰膚齋鏇憲艱襯膚範 )	相似	2024-06-20
IRCT20140903019036N3 (ESMO_GI2024) 人工标引	临床2期	食管癌新辅助	59	Oxaliplatin/Capecitabine (XELOX) regimen	襯願糧壓糧網繭淵遞鹹(餘鬱淵糧淵廠艱願窪餘) = 蓋鬱積鬱淵獵網鏇膚廠鏇顧餘糧窪膚鏇鬱鹹醖 (遞鑰膚齋鏇憲艱襯膚範 )	相似	2024-06-20
ESMO_GI2024	N/A	结直肠癌	-	Oxaliplatin (CRC patients with HSR to OXL)	夢鏇艱襯壓壓艱觸遞構(鬱製繭鏇衊範網構顧選) = OIIS is a rare but potentially fatal complication caused by a type II antibody-mediated hypersensitivity reaction (HSR), with different clinical presentations including autoimmune haemolytic anaemia, acute immune thrombocytopenia (AIT), Evans Syndrome (ES) and thrombotic microangiopathy (TMA) 鹽憲製餘壓網顧製鏇選 (簾繭衊顧網願壓鬱網壓 ) 更多	-	2024-06-20